100 mg Fresofungin Injection

Fresofungin (Anidulafungin) is an intravenous echinocandin antifungal agent. It is semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin was approved for the treatment of candidemia and other Candida infections (intra-abdominal, peritonitis) and esophageal candidiasis in February 2006.

Indications

   Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis)
   Esophageal candidiasis

Packaging/Dosage

Packaging:

Fresofungin is supplied in a combipack containing 1 glass vial and 30 ml vial of sterile water for injections IP as diluent.

Dosage:

Candidemia and other Candida infections (intra-abdominal abscess, and peritonitis)
The recommended dose is a single 200 mg loading dose of Fresofungin on Day 1, followed by 100 mg daily dose thereafter. Duration of treatment should be based on the patients clinical response. In general, antifungal therapy should continue for at least 14 days after the last Positive culture.

Esophageal candidiasis
The recommended dose is a single 100 mg loading dose of Fresofungin on Day 1, followed by 50 mg daily dose thereafter. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms. Duration of treatment should be based on the patients clinical response. Because of the risk of relapse of esophageal candidiasis in patients with HIV infections, suppressive antifungal therapy may be considered after a course of treatment.
No dosing adjustments are required for patients with any degree of renal or hepatic insufficiency, patients using concomitant medications or those in other special populations.